zonisamide

ApprovedWithdrawn
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia, Migraine

Trial Timeline

Aug 1, 2004 โ†’ Jan 1, 2008

About zonisamide

zonisamide is a approved stage product being developed by Eisai for Fibromyalgia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00259636. Target conditions include Fibromyalgia, Migraine.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (6)

NCT IDPhaseStatus
NCT01283256Pre-clinicalCompleted
NCT01136954Phase 3Completed
NCT00659958ApprovedCompleted
NCT01140867ApprovedCompleted
NCT00259636ApprovedWithdrawn
NCT00056576Phase 3Completed

Competing Products

20 competing products in Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
DS-5565 + PlaceboDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
ASP8062 + PlaceboAstellas PharmaPhase 2
52
ASP0819 + PlaceboAstellas PharmaPhase 2
52
DuloxetineShionogiPhase 3
77
Duloxetine 60 mg + PlaceboShionogiPhase 3
77
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
DuloxetineEli LillyApproved
85
duloxetine hydrochloride + placeboEli LillyApproved
85
duloxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
Treatment for FibromyalgiaEli LillyPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77
Eszopiclone + placeboSumitomo PharmaApproved
85